These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4621 related articles for article (PubMed ID: 6583026)

  • 21. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma.
    Van Echo DA; Markus S; Aisner J; Wiernik PH
    Cancer Treat Rep; 1980; 64(8-9):1009-10. PubMed ID: 6893810
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma.
    Schneider RJ; Woodcock TM; Yagoda A
    Cancer Treat Rep; 1980 Jan; 64(1):183-5. PubMed ID: 6892892
    [No Abstract]   [Full Text] [Related]  

  • 23. m-AMSA: a new anticancer agent.
    Rozencweig M; Von Hoff DD; Legha SS; Cysyk RL; Muggia FM
    Recent Results Cancer Res; 1980; 74():250-7. PubMed ID: 6893753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of gamma-irradiation with two new antineoplastic agents, aziridinylbenzoquinone (AZQ) and 4'- (acridinylamino)methanesulfon-m-anisidide (AMSA), in murine tumors in vivo.
    Johnson RK; Wodinsky I; Swiniarski J; Meaney KF; Clement JJ
    Int J Radiat Oncol Biol Phys; 1979 Sep; 5(9):1605-9. PubMed ID: 583418
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia.
    Odaimi M; Andersson BS; McCredie KB; Beran M
    Cancer Res; 1986 Jul; 46(7):3330-3. PubMed ID: 3754787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity of 4'-(9-acridinylamino)methanesulfon-m-anisidide in exponential- and plateau-phase Chinese hamster cell cultures.
    Wilson WR; Giesbrecht JL; Hill RP; Whitmore GF
    Cancer Res; 1981 Jul; 41(7):2809-16. PubMed ID: 6894713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).
    Von Hoff DD; Elson D; Polk G; Coltman C
    Cancer Treat Rep; 1980; 64(2-3):356-8. PubMed ID: 6931630
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase II. Evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma.
    Sordillo PP; Magill GB; Gralla RJ; Golbey RB
    Cancer Treat Rep; 1980; 64(10-11):1129-30. PubMed ID: 6893950
    [No Abstract]   [Full Text] [Related]  

  • 29. Phase II evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer.
    Casper ES; Gralla RJ; Kelsen DP; Natale RB; Sordillo P; Houghton A
    Cancer Treat Rep; 1980; 64(2-3):345-7. PubMed ID: 6893294
    [No Abstract]   [Full Text] [Related]  

  • 30. Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992).
    Hall SW; Friedman J; Legha SS; Benjamin RS; Gutterman JU; Loo TL
    Cancer Res; 1983 Jul; 43(7):3422-6. PubMed ID: 6687834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biliary excretion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in rats: effects of pretreatment with diethyl maleate, phenobarbital, and metyrapone.
    Shoemaker DD; Gormley PE; Cysyk RL
    Drug Metab Dispos; 1980; 8(6):467-8. PubMed ID: 6109618
    [No Abstract]   [Full Text] [Related]  

  • 32. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
    Warrell RP; Straus DJ; Young CW
    Cancer Treat Rep; 1980; 64(10-11):1157-8. PubMed ID: 6893952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma.
    Carroll DS; Kemeny N; Lynch G; Wookcock T
    Cancer Treat Rep; 1980; 64(10-11):1149-50. PubMed ID: 6893951
    [No Abstract]   [Full Text] [Related]  

  • 34. 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
    Kahn SB; Sklaroff R; Lebedda J; Conroy JF; Bulova S; Brodsky I
    Am J Clin Oncol; 1983 Aug; 6(4):493-502. PubMed ID: 6191561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
    Woodcock TM; Schneider RJ; Young CW
    Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I-II study of m-AMSA administered as a continuous infusion.
    Micetich KC; Zwelling LA; Gormley P; Young RC
    Cancer Treat Rep; 1982 Oct; 66(10):1813-7. PubMed ID: 6897013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surgical-adjuvant chemotherapy with AMSA in Lewis lung carcinoma bearing mice.
    Greco C; Zupi G; Corsi A; Calabresi F
    Anticancer Res; 1985; 5(3):297-300. PubMed ID: 3839353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
    Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of AMSA in children with acute leukemia. A Pediatric Oncology Group study.
    Krischer J; Land VJ; Civin CI; Ragab AH; Mahoney DH; Frankel LS
    Cancer; 1984 Jul; 54(2):207-10. PubMed ID: 6586277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage.
    Pommier Y; Minford JK; Schwartz RE; Zwelling LA; Kohn KW
    Biochemistry; 1985 Nov; 24(23):6410-6. PubMed ID: 3002440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 232.